These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now

On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors salivate. The stock briefly rose 8% above where it was before the announcement.But to the ears of other investors, the same two words imply a risk they'd rather not think about. Let's dive in and sort out what's going on, as well as which of these two perspectives is more relevant for those considering a purchase of this stock today.Intellia makes gene therapies for genetic illnesses like hereditary angioedema (HAE). Some of those therapies, like NTLA-2002, one of its investigational medicines for HAE, entail editing the patient's genes directly so as to correct the inborn errors that cause illness. Such approaches are intended to be attempted only once per patient. But if they work as intended, the impact is potentially sufficient to make them symptom-free, potentially for the rest of their lives.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Zum vollständigen Artikel